Literature DB >> 25165112

Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.

Andrew E Armitage1, Koen Deforche2, John J Welch3, Kristel Van Laethem2, Ricardo Camacho4, Andrew Rambaut5, Astrid K N Iversen6.   

Abstract

UNLABELLED: Members of the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like-3 (APOBEC3) innate cellular cytidine deaminase family, particularly APOBEC3F and APOBEC3G, can cause extensive and lethal G-to-A mutations in HIV-1 plus-strand DNA (termed hypermutation). It is unclear if APOBEC3-induced mutations in vivo are always lethal or can occur at sublethal levels that increase HIV-1 diversification and viral adaptation to the host. The viral accessory protein Vif counteracts APOBEC3 activity by binding to APOBEC3 and promoting proteasome degradation; however, the efficiency of this interaction varies, since a range of hypermutation frequencies are observed in HIV-1 patient DNA. Therefore, we examined "footprints" of APOBEC3G and APOBEC3F activity in longitudinal HIV-1 RNA pol sequences from approximately 3,000 chronically infected patients by determining whether G-to-A mutations occurred in motifs that were favored or disfavored by these deaminases. G-to-A mutations were more frequent in APOBEC3G-disfavored than in APOBEC3G-favored contexts. In contrast, mutations in APOBEC3F-disfavored contexts were relatively rare, whereas mutations in contexts favoring APOBEC3F (and possibly other deaminases) occurred 16% more often than average G-to-A mutations. These results were supported by analyses of >500 HIV-1 env sequences from acute/early infection. IMPORTANCE: Collectively, our results suggest that APOBEC3G-induced mutagenesis is lethal to HIV-1, whereas mutagenesis caused by APOBEC3F and/or other deaminases may result in sublethal mutations that might facilitate viral diversification. Therefore, Vif-specific cytotoxic T lymphocyte (CTL) responses and drugs that manipulate the interplay between Vif and APOBEC3 may have beneficial or detrimental clinical effects depending on how they affect the binding of Vif to various members of the APOBEC3 family.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25165112      PMCID: PMC4248940          DOI: 10.1128/JVI.01460-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  98 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.

Authors:  Lubbertus C F Mulder; Marcel Ooms; Susan Majdak; Jordan Smedresman; Caitlin Linscheid; Ariana Harari; Andrea Kunz; Viviana Simon
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

3.  Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007.

Authors:  Catherine A Brennan; Julie Yamaguchi; Sushil G Devare; Greg A Foster; Susan L Stramer
Journal:  Transfusion       Date:  2010-12       Impact factor: 3.157

4.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

5.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

6.  Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious.

Authors:  Feng Gao; Yalu Chen; David N Levy; Joan A Conway; Thomas B Kepler; Huxiong Hui
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Cytidine deamination induced HIV-1 drug resistance.

Authors:  Lubbertus C F Mulder; Ariana Harari; Viviana Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

8.  APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.

Authors:  Andrew E Armitage; Koen Deforche; Chih-Hao Chang; Edmund Wee; Beatrice Kramer; John J Welch; Jan Gerstoft; Lars Fugger; Andrew McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  PLoS Genet       Date:  2012-03-22       Impact factor: 5.917

9.  APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.

Authors:  Yanxing Han; Xiaojun Wang; Ying Dang; Yong-Hui Zheng
Journal:  PLoS Pathog       Date:  2008-07-04       Impact factor: 6.823

10.  Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk.

Authors:  Mayumi Imahashi; Taisuke Izumi; Dai Watanabe; Junji Imamura; Kazuhiro Matsuoka; Hirotaka Ode; Takashi Masaoka; Kei Sato; Noriyo Kaneko; Seiichi Ichikawa; Yoshio Koyanagi; Akifumi Takaori-Kondo; Makoto Utsumi; Yoshiyuki Yokomaku; Takuma Shirasaka; Wataru Sugiura; Yasumasa Iwatani; Tomoki Naoe
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more
  10 in total

Review 1.  The Road Less Traveled: HIV's Use of Alternative Routes through Cellular Pathways.

Authors:  Ailie Marx; Akram Alian
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

2.  Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.

Authors:  Matthew M Hernandez; Audrey Fahrny; Ravi Sachidanandam; Roberto F Speck; Viviana Simon; Anitha Jayaprakash; Gustavo Gers-Huber; Marsha Dillon-White; Annette Audigé; Lubbertus C F Mulder
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

3.  Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.

Authors:  Sara Pautasso; Ganna Galitska; Valentina Dell'Oste; Matteo Biolatti; Rachele Cagliani; Diego Forni; Marco De Andrea; Marisa Gariglio; Manuela Sironi; Santo Landolfo
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

Review 4.  APOBEC3 Proteins in Viral Immunity.

Authors:  Spyridon Stavrou; Susan R Ross
Journal:  J Immunol       Date:  2015-11-15       Impact factor: 5.422

5.  Clustered mutations in hominid genome evolution are consistent with APOBEC3G enzymatic activity.

Authors:  Yishay Pinto; Orshay Gabay; Leonardo Arbiza; Aaron J Sams; Alon Keinan; Erez Y Levanon
Journal:  Genome Res       Date:  2016-04-07       Impact factor: 9.043

6.  APOBEC3 proteins can copackage and comutate HIV-1 genomes.

Authors:  Belete A Desimmie; Ryan C Burdick; Taisuke Izumi; Hibiki Doi; Wei Shao; W Gregory Alvord; Kei Sato; Yoshio Koyanagi; Sara Jones; Eleanor Wilson; Shawn Hill; Frank Maldarelli; Wei-Shau Hu; Vinay K Pathak
Journal:  Nucleic Acids Res       Date:  2016-07-20       Impact factor: 16.971

Review 7.  The Role of APOBECs in Viral Replication.

Authors:  Wendy Kaichun Xu; Hyewon Byun; Jaquelin P Dudley
Journal:  Microorganisms       Date:  2020-11-30

8.  Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation.

Authors:  Krista A Delviks-Frankenberry; Olga A Nikolaitchik; Ryan C Burdick; Robert J Gorelick; Brandon F Keele; Wei-Shau Hu; Vinay K Pathak
Journal:  PLoS Pathog       Date:  2016-05-17       Impact factor: 6.823

9.  APOBEC3G Regulation of the Evolutionary Race Between Adaptive Immunity and Viral Immune Escape Is Deeply Imprinted in the HIV Genome.

Authors:  Faezeh Borzooee; Krista D Joris; Michael D Grant; Mani Larijani
Journal:  Front Immunol       Date:  2019-01-11       Impact factor: 7.561

Review 10.  Human APOBEC3 Variations and Viral Infection.

Authors:  Shiva Sadeghpour; Saeideh Khodaee; Mostafa Rahnama; Hamzeh Rahimi; Diako Ebrahimi
Journal:  Viruses       Date:  2021-07-14       Impact factor: 5.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.